[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ticagrelor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ticagrelor":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100613612","effect-of-fan-application-in-preventing-ticagrelor-associated-dyspnea-100613612",false,"NCT07268859","Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea","Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.","ACS","Inclusion Criteria:\n\n* Between the ages of 18 and 65,\n* No severe hearing and vision problems,\n* Can speak and understand Turkish,\n* Easy to communicate with,\n* First-time sufferer of acute coronary syndrome (ACS) for the first time,\n* Decided to start ticagrelor therapy,\n* Able to adapt to treatment,\n* Individuals who volunteered to participate in the research.\n\nExclusion Criteria:\n\n* Having any problem that prevents you from communicating cognitively, emotionally and verbally,\n* Obstructive sleep abnormalities,\n* Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),\n* With metabolic abnormalities,\n* Intubated after the procedure,\n* Previously treated with ticagrelor,\n* Individuals who did not volunteer to participate in the study. Losses to follow up\n* Individuals who wish to leave the study voluntarily.\n* Saturation value below 95%,\n* The one with the arrest,\n* Who will not be able to fulfill the requirements of the work,\n* Individuals with life-threatening conditions",true,"ALL","18 Years","65 Years",{"count":22,"type":23},110,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.",[29,30,31],"Acute Coronary Syndromes","Ticagrelor","Dyspnea",[33,30,34,31,35],"Nursing","Hand fan therapy","Non-pharmacological intervention","RECRUITING","2025-12-04",{"date":39,"type":40},"2025-12-08","ACTUAL",{"date":42,"type":40},"2025-03-15",{"date":44,"type":23},"2026-01-30",{"name":46,"class":47},"Acibadem University","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":76,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":59,"type":23},50,[61],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[64,30,65,66,67,68,69,70,71,72,73,74,75],"ACS - Acute Coronary Syndrome","Microbiota","Platelet Aggregation","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[77,78,79,80,81,82,83,84,85,86],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","NOT_YET_RECRUITING","2025-09-25",{"date":90,"type":40},"2025-10-02",{"date":92,"type":23},"2026-01-01",{"date":94,"type":23},"2027-06-30",{"name":96,"class":47},"Collegium Medicum w Bydgoszczy",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100497984","imapct-of-biomarkers-on-pharmacodynamics-and-bleeding-risk-of-direct-oral-anticoagulants-and-ticagrelor-study-ii-100497984","NCT05764356","Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II","Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II (IMPACT 2)","Inclusion Criteria:\n\n(I) Chinese Patients taking NOACs\n\n* In accordance with anticoagulation indications of NOACs, include prevention of thrombosis in non valvular atrial fibrillation, prevention and treatment of deep vein thrombosis \u002F pulmonary embolism and prevention of thrombosis after knee \u002F hip replacement;\n* More than 18 years of age, male or female;\n* Never received NOACs in a month and intend to take NOACs or have received NOACs for more than one week continuously;\n* sign informed consent.\n\n(II) Chinese Patients taking ticagrelor\n\n* With diagnosis of acute coronary syndrome (ACS), included unstable angina, non ST segment elevation myocardial infarction and ST segment elevation myocardial infarction;\n* More than 18 years of age, male or female;\n* Never received ticagrelor in a month and intend to take ticagrelor or have received ticagrelor for more than one week continuously#\n* sign informed consent.\n\nExclusion Criteria:\n\n* With history of immunodeficiency disease, including positive HIV index;\n* Positive Hepatitis B surface antigen (HBsAg) and HCV index;\n* Combined therapy of CYP3A4 strong inhibitors and P-gp inhibitors (e.g., systemic pyrrole antifungal agents such as ketoconazole, itraconazole, voriconazole and posaconazole; human immunodeficiency virus (HIV) - protease inhibitors such as ritonavir), CYP3A4 strong inducers and P-gp inducers (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine, St. John's Wort, etc.) in 14 days before treatment with NOACs;\n* Severe liver dysfunction and abnormal renal function;\n* Include contraindications of antithrombosis, such as hypersensitivity, active bleeding, moderate or severe liver disease, previous history of intracranial hemorrhage, gastrointestinal hemorrhage in the past 6 months and major operation within 30 days.",{"count":106,"type":23},2000,"OBSERVATIONAL","Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%. Novel oral anticoagulant drugs (NOACs, including rivaroxaban, apixaban, edoxaban, dabigatran, etc.) and novel antiplatelet drug ticagrelor have the advantages of convenient use and no need for monitoring. But novel oral antithrombotic drugs also increase the risk of bleeding, and there is currently a lack of effective antagonists when antithrombosis is excessive or emergency surgery is required. At present, there are few studies on the causes of individual differences in novel antithrombotic drugs, and there is a lack of predictable biomarkers or drug genotypes, especially in China. Therefore, on the basis of previous studies on NOACs and ticagrelor individualized medication cohorts, this study plans to establish a validation cohort for novel antithrombotic drugs bleeding related biomarkers, conduct multi-omics testing and long-term follow-up, and explore markers related to pharmacodynamics of antithrombotic drugs, adverse bleeding reactions and clinical outcomes.",[110,111,112,113,114,115,30,116,117,118,119,120],"Novel Oral Anticoagulants","NOACs","Rivaroxaban","Apixaban","Edoxaban","Dabigatran","Pharmacodynamics","Pharmacogenomics","RNA Profile","Bleeding","Biomarker","2023-03-01",{"date":123,"type":40},"2023-03-10",{"date":125,"type":23},"2023-03",{"date":127,"type":23},"2027-12",{"name":129,"class":47},"Peking University First Hospital",6]